Results 41 to 50 of about 149,298 (164)

Functional properties and sequence variation of HTLV-1 p13

Retrovirology, 2020
Human T cell leukemia virus type-1 (HTLV-1) was the first retrovirus found to cause cancer in humans, but the mechanisms that drive the development of leukemia and other diseases associated with HTLV-1 infection remain to be fully understood. This review
Maria Omsland, Micol Silic-Benussi, Ramona Moles, Sarkis Sarkis, Damian F. J. Purcell, David Yurick, Georges Khoury, Donna M. D’Agostino, Vincenzo Ciminale, Genoveffa Franchini   +9 more
doaj   +1 more source

mRNA vaccine in cancer therapy: Current advance and future outlook

Clinical and Translational Medicine, 2023
Messenger ribonucleic acid (mRNA) vaccines are a relatively new class of vaccines that have shown great promise in the immunotherapy of a wide variety of infectious diseases and cancer.
Youhuai Li, Mina Wang, Xueqiang Peng, Yingying Yang, Qishuang Chen, Jiaxing Liu, Qing She, Jichao Tan, Chuyuan Lou, Zehuan Liao, Xuexin Li   +10 more
doaj   +1 more source

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment

Frontiers in Immunology, 2023
New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA) family, and has been identified as one of the most immunogenic tumor-associated antigens (TAAs) among the family members.
Hong Zhou, Hong Zhou, Hong Zhou, Yipeng Ma, Yipeng Ma, Fenglan Liu, Fenglan Liu, Bin Li, Bin Li, Dongjuan Qiao, Dongjuan Qiao, Peigen Ren, Mingjun Wang, Mingjun Wang   +13 more
doaj   +1 more source

Lung Cancer Vaccines [PDF]

The Cancer Journal, 2011
To date, in lung cancer, early attempts to modulate the immune system via vaccine-based therapeutics have been unsuccessful. An improved understanding of tumor immunology has facilitated the production of more sophisticated lung cancer vaccines. It is anticipated that it will likely require multiple epitopes of a diverse set of genes restricted to ...
Ronan J, Kelly, Giuseppe, Giaccone
openaire   +2 more sources

High expression of Rex-orf-I and HBZ mRNAs and bronchiectasis in lung of HTLV-1A/C infected macaques

Nature Communications
HTLV-1 type-A rarely causes lung disease in humans, whereas HTLV-1 type-C is more frequently associated with respiratory failure and premature death.
Sarkis Sarkis, Anna Gutowska, Mohammad Arif Rahman, Luca Schifanella, Katherine C. Goldfarbmuren, Massimiliano Bissa, Ramona Moles, Christina Ramirez, Elijah F. Edmondson, Andrew Warner, Melvin Doster, Isabela Silva de Castro, Robyn Washington-Parks, Sophia Brown, Joshua Kramer, Matthew W. Breed, Kristin E. Killoran, Yogita Jethmalani, Leonid Serebryannyy, Damian FJ. Purcell, Cynthia A. Pise-Masison, Genoveffa Franchini   +21 more
doaj   +1 more source

HTLV-1 p13 Protein Hijacks Macrophage Polarization and Promotes T-Cell Recruitment

Viruses
The human T-cell leukemia type-1 (HTLV-1) retrovirus establishes chronic life-long infection in a fraction of infected individuals associated with severe pathological conditions. Although the mechanism driving disease development is not fully understood,
Ramona Moles, Maria Omsland, Cynthia A. Pise-Masison, Jeffrey J. Subleski, Daniel W. McVicar, Sarkis Sarkis, Anna Gutowska, Luca Schifanella, Melvin Doster, Robyn Washington-Parks, Vincenzo Ciminale, Genoveffa Franchini   +11 more
doaj   +1 more source

Application of Nanotechnology in Therapeutic Cancer Vaccines

Advanced NanoBiomed Research, 2023
Cancer vaccines stimulate the immune system within the body by introducing tumor antigens in various forms, such as tumor cells, tumor‐related proteins or peptides, and genes expressing tumor antigens, into the body.
Jianmei Guo, Lin Tang, Kelin Li, Qingxin Ma, Shuda Luo, Ruoyu Cheng, Chaoyong Liu   +6 more
doaj   +1 more source

Aging and Cancer Vaccines [PDF]

Critical Reviews in Oncogenesis, 2013
Cancer vaccination is less effective at old than at young age, due to T cell unresponsiveness. This is caused by age-related changes of the immune system. Major immune defects at older age are lack of naive T cells, impaired activation pathways of T cells and antigen-presenting cells (APC), and age-related changes in the tumor microenvironment (TME ...
Claudia, Gravekamp, Dinesh, Chandra
openaire   +2 more sources

HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques

Nature Communications
Simian or Human immunodeficiency virus (SIV or HIV) vaccines based on V1-deleted envelope virus-like particles, delivered by the DNA/ALVAC platforms, followed by the ΔV1gp120 boost formulated in Alum, protect 50% and 80% of macaques from mucosal ...
Massimiliano Bissa, Mohammad Arif Rahman, Luca Schifanella, Katherine C. Goldfarbmuren, Isabela Silva de Castro, Emmanuel K. Woode, Anna Gutowska, Melvin N. Doster, Sophia Brown, Sarkis Sarkis, Neil R. Kanchetty, Cynthia A. Pise-Masison, Robyn Washington-Parks, Katherine McKinnon, Shraddha Basu, Jiae Kim, Ryan Alving, Dominic Paquin-Proulx, Kombo F. N’guessan, Xiaoying Shen, David C. Montefiori, Timothy Cardozo, Gary R. Matyas, Mangala Rao, Genoveffa Franchini   +24 more
doaj   +1 more source

Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization

Cell Reports, 2019
Summary: Broadly HIV-1 neutralizing VRC01 class antibodies target the CD4-binding site of Env. They are derived from VH1-2∗02 antibody heavy chains paired with rare light chains expressing 5-amino acid-long CDRL3s.
K. Rachael Parks, Anna J. MacCamy, Josephine Trichka, Matthew Gray, Connor Weidle, Andrew J. Borst, Arineh Khechaduri, Brittany Takushi, Parul Agrawal, Javier Guenaga, Richard T. Wyatt, Rhea Coler, Michael Seaman, Celia LaBranche, David C. Montefiori, David Veesler, Marie Pancera, Andrew McGuire, Leonidas Stamatatos   +18 more
doaj   +1 more source